2019 Annual Report Contents

Total Page:16

File Type:pdf, Size:1020Kb

2019 Annual Report Contents MEDICLINIC INTERNATIONAL PLC MEDICLINIC INTERNATIONAL | ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2019 ANNUAL 2019 ANNUAL REPORT CONTENTS 4 At a glance GOVERNANCE AND REMUNERATION 103 Chairman’s Introduction STRATEGIC REPORT 104 Board of Directors Business overview 110 Group Executive Committee 10 Performance summary 114 Corporate Governance Statement 12 Chairman’s Statement 136 Audit and Risk Committee Report 16 Business model 150 Clinical Performance and Sustainability 18 Our strategy, goals and progress Committee Report 22 Investment case 154 Nomination Committee Report 23 Five-year summary 159 Directors’ Remuneration Report Performance and future outlook 179 Statement of Directors’ Responsibilities 24 Chief Executive Officer’s Review 29 Financial Review FINANCIAL STATEMENTS 40 Value added statement 182 Group Financial Statements 41 Clinical services overview 280 Company Financial Statements Risk management ADDITIONAL INFORMATION 55 Risk management, principal risks and uncertainties 296 Shareholder information 60 Viability statement 300 Company information Divisional reviews 302 Forward-looking statements 62 Divisional Review – Switzerland 303 Glossary 67 Divisional Review – Southern Africa 71 Divisional Review – UAE Non-financial performance 76 Sustainable development overview 100 Non-financial information statement OVERVIEW ADAPTING LOSS OF MEDICLINIC TO THE CHANGING GLOBAL £151M* HEALTHCARE impacted by non-cash ENVIRONMENT Hirslanden and Spire impairment charges and is a priority with focus other exceptional items throughout the Group to invest across the continuum * Refer to loss attributable to equity holders. of care £232M 750 000 INPATIENT ADMISSIONS SIGNIFICANT across the Group as the demand ONGOING for quality healthcare services INVESTMENT remains strong across the Group supporting patient experience, clinical excellence, maintenance, upgrades and expansion REVENUE UP 2% to £2 932m; up 4% ADJUSTED EARNINGS in constant currency PER SHARE DOWN 10% ADJUSTED to 26.9 pence EBITDA DOWN 4% TOTAL DIVIDEND FOR to £493m; down 2% THE YEAR in constant currency reflecting the financial 7.9 PENCE impact of regulatory changes on Hirslanden MEDICLINIC INTERNATIONAL PLC | 2019 ANNUAL REPORT 1 2 MEDICLINIC INTERNATIONAL PLC | 2019 ANNUAL REPORT REPORT PROFILE REPORT STRATEGIC SCOPE, BOUNDARY AND REPORTING CYCLE This annual report and financial statements (“Annual Reporting] Regulations 2016 aimed at improving the Report”) of Mediclinic International plc (the “Company” transparency of companies regarding non-financial and or “Mediclinic”) presents the financial results and the diversity information), where relevant. The Company economic, social and environmental performance of complied with all the provisions of the UK Corporate Mediclinic for the financial year ended 31 March 2019 Governance Code, other than the exceptions explained GOVERNANCE AND REMUNERATION GOVERNANCE (the “reporting period”) and reports on the operations in the Corporate Governance Statement on page 114 of the Company’s subsidiaries in Switzerland, Southern of this Annual Report. The Company’s reporting on Africa and the United Arab Emirates (“UAE”) (collectively, sustainable development included in this report the “Group”). (supplemented by the Sustainable Development Report which is available on the Company’s website at REPORTING PRINCIPLES www.mediclinic.com) was done in accordance with This Annual Report contains information that is deemed the Global Reporting Initiative Sustainability Reporting useful and relevant to stakeholders, with due regard to Standards 2016 (“GRI Standards”) and the non-financial their expectations through continuous engagement or reporting regulations referred to above. information that the board of Directors of Mediclinic (the “Board” or the “Board of Directors”) believes may EXTERNAL AUDIT AND ASSURANCE influence stakeholders’ perception or decision-making. The Company’s annual financial statements and the The information aims to provide stakeholders with an Group’s consolidated annual financial statements were understanding of the Group’s financial, economic, social audited by the Group’s independent external auditor, and environmental impacts to enable them to evaluate PricewaterhouseCoopers LLP (the “external auditor”), in the ability of Mediclinic to create and sustain value. accordance with International Standards of Auditing (UK). This Annual Report was prepared in accordance with The Group follows various other voluntary external FINANCIAL STATEMENTS the International Financial Reporting Standards (“IFRS”), accreditation, certification and assurance initiatives, the listing rules of the London Stock Exchange (“LSE”), the complementing the Group’s combined assurance model, listings requirements of the JSE Ltd (“JSE”), the United as reported on in the Risk management section of this Kingdom (“UK”) Corporate Governance Code and the Annual Report. The Group believes that this adds to the UK Companies Act 2006 (including the Companies, transparency and reliability of information reported to Partnerships and Group [Accounts and Non-Financial its stakeholders. CONTRIBUTION TO CONTRIBUTION TO CONTRIBUTION TO REVENUE* ADJUSTED EBITDA* ADJUSTED EARNINGS* £677m £88m £46m £1m (£1m) ADDITIONAL INFORMATION ADDITIONAL £219m £1 368m £2 932m £493m £80m £198m £886m £187m £72m Hirslanden Mediclinic Southern Africa Mediclinic Middle East Corporate * The Group uses adjusted income statement reporting as non-IFRS measures in evaluating performance. Refer to the Financial Review on page 31 for an explanation and for a reconciliation to the equivalent IFRS measures. MEDICLINIC INTERNATIONAL PLC | 2019 ANNUAL REPORT 3 AT A GLANCE TO ENHANCE THE QUALITY OF LIFE. Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets. UNITED KINGDOM 29.9% investment in Spire Healthcare Group plc. For more information, please refer to page 38 and visit: www.spirehealthcare.co.uk SWITZERLAND With continuing regulatory changes during the year in Switzerland, Hirslanden is adapting to the evolving outpatient environment while delivering ongoing cost management and efficiency savings which, along with seasonal benefits, delivered an improved second-half financial performance. For more information, please refer to page 62 and visit: www.hirslanden.ch UNITED ARAB EMIRATES The new Mediclinic Parkview Hospital in Dubai was successfully opened in September 2018, six months ahead of the original schedule. Revenue and EBITDA growth achieved during the year are expected to continue over the medium term as the benefits from investments support the operational delivery of the division. For more information, please refer to page 71 and visit: www.mediclinic.ae SOUTHERN AFRICA Mediclinic’s continued strategic focus to invest across the continuum of care resulted in the expansion of the division’s sub-acute hospital, day case and outpatient clinics during the year. The investment in the Intercare group, completed in November 2018, supported revenue and patient growth with a strong operational focus delivering broadly stable EBITDA margins. For more information, please refer to page 67 or visit: www.mediclinic.co.za www.mhr.co.za www.er24.co.za 4 MEDICLINIC INTERNATIONAL PLC | 2019 ANNUAL REPORT About Mediclinic Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in REPORT STRATEGIC Switzerland, Southern Africa (South Africa and Namibia) and the UAE. The Group’s core purpose is to enhance the quality of life. The Company’s primary listing is on the LSE in the UK, with secondary listings on United Kingdom the JSE in South Africa and the Namibian AND REMUNERATION GOVERNANCE Stock Exchange (“NSX”) in Namibia. The Switzerland Group’s registered office is in London, UK. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading UK-based private healthcare group listed on the LSE. United Arab Emirates FINANCIAL STATEMENTS 77 5 Hospitals Sub-acute hospitals ADDITIONAL INFORMATION ADDITIONAL 12 21 Southern Africa Day case clinics Outpatient clinics 32 398 11 359 445 Employees Inpatient beds Theatres MEDICLINIC INTERNATIONAL PLC | 2019 ANNUAL REPORT 5 AT A GLANCE (CONTINUED) “WE ARE ADAPTING THE BUSINESS TO ADDRESS THE CHANGING LANDSCAPE AND TO CAPITALISE ON GROWING OPPORTUNITIES IN THE GLOBAL HEALTHCARE SERVICES SECTOR.” Dr Ronnie van der Merwe Chief Executive Officer 12 DAY 11 359 INPATIENT 77 HOSPITALS CASE CLINICS BEDS Switzerland 18 Switzerland 2 Switzerland 1 916 Southern Africa 52 Southern Africa 8 Southern Africa 8 517 South Africa 49 UAE 2 UAE 926 Namibia 3 UAE 7 5 SUB-ACUTE 21 OUTPATIENT 445 HOSPITALS CLINICS THEATRES Southern Africa 5 Switzerland 3 Switzerland 112 UAE 18 Southern Africa 296 UAE 37 32 398 EMPLOYEES Permanent Full-time equivalents Switzerland 10 442 8 303 Southern Africa 15 804 19 646 (including agency employees) UAE 6 152 6 152 EMPLOYEE ENGAGEMENT CONTROLLABLE EMPLOYEE PATIENT EXPERIENCE (MAXIMUM SCORE OF 5) TURNOVER Switzerland 4.01 Group 6.9% Switzerland 87.6% Southern Africa 3.94 Switzerland 7.6% Southern Africa 82.2% UAE 4.02 Southern Africa 6.7% UAE 85.6% Refer to page 85 for more information. Refer to page 80 for more information. Refer to page 43 for more information. Refer to the Investments in Subsidiaries,
Recommended publications
  • Parker Review
    Ethnic Diversity Enriching Business Leadership An update report from The Parker Review Sir John Parker The Parker Review Committee 5 February 2020 Principal Sponsor Members of the Steering Committee Chair: Sir John Parker GBE, FREng Co-Chair: David Tyler Contents Members: Dr Doyin Atewologun Sanjay Bhandari Helen Mahy CBE Foreword by Sir John Parker 2 Sir Kenneth Olisa OBE Foreword by the Secretary of State 6 Trevor Phillips OBE Message from EY 8 Tom Shropshire Vision and Mission Statement 10 Yvonne Thompson CBE Professor Susan Vinnicombe CBE Current Profile of FTSE 350 Boards 14 Matthew Percival FRC/Cranfield Research on Ethnic Diversity Reporting 36 Arun Batra OBE Parker Review Recommendations 58 Bilal Raja Kirstie Wright Company Success Stories 62 Closing Word from Sir Jon Thompson 65 Observers Biographies 66 Sanu de Lima, Itiola Durojaiye, Katie Leinweber Appendix — The Directors’ Resource Toolkit 72 Department for Business, Energy & Industrial Strategy Thanks to our contributors during the year and to this report Oliver Cover Alex Diggins Neil Golborne Orla Pettigrew Sonam Patel Zaheer Ahmad MBE Rachel Sadka Simon Feeke Key advisors and contributors to this report: Simon Manterfield Dr Manjari Prashar Dr Fatima Tresh Latika Shah ® At the heart of our success lies the performance 2. Recognising the changes and growing talent of our many great companies, many of them listed pool of ethnically diverse candidates in our in the FTSE 100 and FTSE 250. There is no doubt home and overseas markets which will influence that one reason we have been able to punch recruitment patterns for years to come above our weight as a medium-sized country is the talent and inventiveness of our business leaders Whilst we have made great strides in bringing and our skilled people.
    [Show full text]
  • MTS Bondspro
    Press Release 30 May 2018 FTSE UK Index Series Quarterly Review June 2018 GVC Holdings and Ocado Group to join FTSE 100 Mediclinic International and G4S to enter FTSE 250 in rebalance FTSE Russell, the global index provider, confirms today that GVC Holdings and Ocado Group will be joining the FTSE 100 Index. In the rebalance, Mediclinic International and G4S will leave the FTSE 100 Index and enter the FTSE 250 Index. The rules-driven, impartial quarterly reviews ensure the indexes continue to portray an accurate reflection of the market they represent, and form an essential component to the management of the indexes. The FTSE 250 Index will see the following changes (in alphabetical order), in addition to the amendments described above. Entering FTSE 250 Index Exiting FTSE 250 Index Energean Oil & Gas Marstons Integrafin Holdings Pets At Home Group Laird Purecircle Premier Oil Woodford Patient Capital Trust FTSE Russell operates a reserve list for the FTSE 100 Index, to be used in the event of a corporate action occurring between reviews e.g. merger, acquisition, delisting or suspension. In such cases, the reserve list constituent with the largest market capitalisation (on the date of the corporate action) will replace the outgoing constituent. With immediate effect, the following reserve list for FTSE 100 will be used: Weir Group Rightmove Mediclinic International Spirax-Sarco Engineering Kaz Minerals Wood Group (John) All changes from this review will be implemented at the close of business on Friday, 15 June 2018 and take effect from the start of trading on Monday, 18 June 2018.
    [Show full text]
  • Press Release
    PRESS RELEASE Geneva, 9 September 2019 HIRSLANDEN CLINIQUE LA COLLINE JOINS LAVER CUP AS OFFICIAL MEDICAL PARTNER Hirslanden Clinique La Colline has been selected by the Laver Cup to become its official medical partner in Geneva, September 20-22, 2019. The Laver Cup today announced its official medical partnership with Hirslanden Clinique La Colline, who’s recently inaugurated Sports Medicine Center has been recognized by Swiss Olympic as Sport Medical Center and professional osteopathy services in the tennis field. Hirslanden Clinique La Colline will be working with Laver Cup and ATP Physiotherapists to provide dedicated treatment and massage therapy services during the tournament. “We are delighted to become the official medical partner of the Laver Cup in Geneva. With our combined expertise in sports medicine, orthopedics and osteopathy, our goal is to enable Team Europe and Team World to showcase the best of their abilities in Geneva. Performance is a matter of preparation and discipline”, says Gilles Rufenacht, Director of Hirslanden Clinique La Colline in Geneva. “We look forward to working with the professional team at Hirslanden at the Laver Cup in Geneva. Their experienced practitioners will be a key asset for all the players, and will ensure both teams have access to the services they need to prepare for what promises to be an incredible weekend of tennis action,” Laver Cup CEO Steve Zacks said. “ Information: Hirslanden Clinique La Colline Laver Cup Magali Dauwalder Prue Ryan Head of Communications Head of Public Relations T +41 79 107 56 76 +61 419 308 369 [email protected] [email protected] www.hirslanden.ch Hirslanden Private Hospital Group As of 31 March 2019, the Hirslanden Private Hospital Group consists of 18 hospitals in 11 cantons, many of which have an integrated outpatient surgery centre and emergency department.
    [Show full text]
  • COVID-19 - ESSKA Guidelines and Recommendations for Resuming Elective Surgery Caroline Mouton, Michael Hirschmann, Matthieu Ollivier, Romain Seil, Jacques Menetrey
    COVID-19 - ESSKA guidelines and recommendations for resuming elective surgery Caroline Mouton, Michael Hirschmann, Matthieu Ollivier, Romain Seil, Jacques Menetrey To cite this version: Caroline Mouton, Michael Hirschmann, Matthieu Ollivier, Romain Seil, Jacques Menetrey. COVID- 19 - ESSKA guidelines and recommendations for resuming elective surgery. Journal of Experimental Orthopaedics, Springer Verlag, 2020, 7 (1), pp.28. 10.1186/s40634-020-00248-4. hal-03175930 HAL Id: hal-03175930 https://hal.archives-ouvertes.fr/hal-03175930 Submitted on 22 Mar 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Mouton et al. Journal of Experimental Orthopaedics (2020) 7:28 Journal of https://doi.org/10.1186/s40634-020-00248-4 Experimental Orthopaedics REVIEW Open Access COVID-19 - ESSKA guidelines and recommendations for resuming elective surgery Caroline Mouton1,2, Michael T. Hirschmann3, Matthieu Ollivier4, Romain Seil1,2 and Jacques Menetrey5,6* Abstract The roadmap to elective surgery resumption after this COVID-19 pandemic should be progressive and cautious. The aim of this paper was to give recommendations and guidelines for resuming elective orthopedic surgery in the safest environment possible.
    [Show full text]
  • Stoxx® Europe 600 Index
    STOXX® EUROPE 600 INDEX Components1 Company Supersector Country Weight (%) NESTLE Food & Beverage CH 2.51 NOVARTIS Health Care CH 2.02 HSBC Banks GB 2.01 ROCHE HLDG P Health Care CH 1.63 TOTAL Oil & Gas FR 1.49 ROYAL DUTCH SHELL A Oil & Gas GB 1.42 BRITISH AMERICAN TOBACCO Personal & Household Goods GB 1.34 BP Oil & Gas GB 1.31 SIEMENS Industrial Goods & Services DE 1.12 BCO SANTANDER Banks ES 1.08 SAP Technology DE 1.08 ALLIANZ Insurance DE 1.04 BAYER Health Care DE 0.97 BASF Chemicals DE 0.96 SANOFI Health Care FR 0.93 GLAXOSMITHKLINE Health Care GB 0.91 NOVO NORDISK B Health Care DK 0.91 BNP PARIBAS Banks FR 0.89 ASTRAZENECA Health Care GB 0.86 DIAGEO Food & Beverage GB 0.85 DAIMLER Automobiles & Parts DE 0.85 ANHEUSER-BUSCH INBEV Food & Beverage BE 0.84 UNILEVER NV Personal & Household Goods NL 0.84 ASML HLDG Technology NL 0.84 LVMH MOET HENNESSY Personal & Household Goods FR 0.82 VODAFONE GRP Telecommunications GB 0.75 UBS GROUP Banks CH 0.72 PRUDENTIAL Insurance GB 0.69 ING GRP Banks NL 0.69 LLOYDS BANKING GRP Banks GB 0.68 AIRBUS Industrial Goods & Services FR 0.68 UNILEVER PLC Personal & Household Goods GB 0.65 GLENCORE PLC Basic Resources GB 0.65 RIO TINTO Basic Resources GB 0.61 AXA Insurance FR 0.59 VINCI Construction & Materials FR 0.57 INTESA SANPAOLO Banks IT 0.55 RECKITT BENCKISER GRP Personal & Household Goods GB 0.55 BCO BILBAO VIZCAYA ARGENTARIA Banks ES 0.55 L'OREAL Personal & Household Goods FR 0.54 AIR LIQUIDE Chemicals FR 0.54 DEUTSCHE TELEKOM Telecommunications DE 0.54 DANONE Food & Beverage FR 0.53 ZURICH INSURANCE
    [Show full text]
  • FTSE UK 100 ESG Select
    2 FTSE Russell Publications 19 August 2021 FTSE UK 100 ESG Select Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country 3i Group 0.83 UNITED KINGDOM Halfords Group 0.06 UNITED KINGDOM Prudential 2.67 UNITED KINGDOM 888 Holdings 0.08 UNITED KINGDOM Harbour Energy PLC 0.01 UNITED KINGDOM Rathbone Brothers 0.08 UNITED KINGDOM Anglo American 2.62 UNITED KINGDOM Helical 0.03 UNITED KINGDOM Reckitt Benckiser Group 3.01 UNITED KINGDOM Ashmore Group 0.13 UNITED KINGDOM Helios Towers 0.07 UNITED KINGDOM Rio Tinto 4.8 UNITED KINGDOM Associated British Foods 0.65 UNITED KINGDOM Hiscox 0.21 UNITED KINGDOM River and Mercantile Group 0.01 UNITED KINGDOM Aviva 1.18 UNITED KINGDOM HSBC Hldgs 6.33 UNITED KINGDOM Royal Dutch Shell A 4.41 UNITED KINGDOM Barclays 2.15 UNITED KINGDOM Imperial Brands 1.09 UNITED KINGDOM Royal Dutch Shell B 3.85 UNITED KINGDOM Barratt Developments 0.52 UNITED KINGDOM Informa 0.56 UNITED KINGDOM Royal Mail 0.39 UNITED KINGDOM BHP Group Plc 3.29 UNITED KINGDOM Intermediate Capital Group 0.44 UNITED KINGDOM Schroders 0.29 UNITED KINGDOM BP 4.66 UNITED KINGDOM International Personal Finance 0.02 UNITED KINGDOM Severn Trent 0.44 UNITED KINGDOM British American Tobacco 4.75 UNITED KINGDOM Intertek Group 0.66 UNITED KINGDOM Shaftesbury 0.12 UNITED KINGDOM Britvic 0.19 UNITED KINGDOM IP Group 0.09 UNITED KINGDOM Smith (DS) 0.4 UNITED KINGDOM BT Group 1.26 UNITED KINGDOM Johnson Matthey 0.43 UNITED KINGDOM Smurfit Kappa Group 0.76 UNITED KINGDOM Burberry Group 0.62 UNITED KINGDOM Jupiter Fund Management 0.09 UNITED KINGDOM Spirent Communications 0.11 UNITED KINGDOM Cairn Energy 0.05 UNITED KINGDOM Kingfisher 0.57 UNITED KINGDOM St.
    [Show full text]
  • FTSE Russell Publications
    2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore
    [Show full text]
  • Prospectus Relating to Mediclinic Combination
    NOTICE IMPORTANT: You must read the following before continuing. The following applies to the document following this notice, whether received by email or otherwise received as a result of electronic communication. You are advised to read this disclaimer carefully before reading, accessing or making any other use of the document. In accessing the document, you agree to be bound by the following terms and conditions, including any modifications to them, each time you receive any information as a result of such access. NOTHING IN THIS ELECTRONIC TRANSMISSION CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE FOLLOWING DOCUMENT MAY NOT BE FORWARDED OR DISTRIBUTED TO ANY OTHER PERSON AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THIS DOCUMENT IN WHOLE OR IN PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE U.S. SECURITIES ACT OF 1933 (THE ‘‘SECURITIES ACT’’) OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS. This document does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdiction where such offer or sale would be unlawful. The shares that may be received in the business combination described in the following document (the ‘‘Combination’’) have not been, and will not be, registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction in the United States, and may only be offered or sold in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 802 under the Securities Act.
    [Show full text]
  • SAVANNAH Q3 2020 BOARD REVIEW an Analysis of the FTSE 100 & FTSE 250 Executive and Non-Executive Board Appointments in Q3 2020 INTRODUCTION
    www.savannah-group.com SAVANNAH Q3 2020 BOARD REVIEW An analysis of the FTSE 100 & FTSE 250 Executive and Non-Executive Board appointments in Q3 2020 INTRODUCTION I am pleased to present our analysis of the executive director appointments already in the first 9 appointments to the FTSE 100 and FTSE 250 boards months. in the third quarter of 2020. As usual, we report the appointments of executive and non-executive Clearly, there has been a catch up and a quick directors to the boards of these companies, identify extrapolation of these numbers shows that we will the trends and we name individuals concerned. see around 100 executive director appointments to the FTSE 350 companies this year. This is still Just as this report was being finalised, we hosted well short of the 2018 numbers, and we have not a webinar to discuss “Boardroom Gender Diversity yet seen the impact of the Covid-19 lockdown. – Unfinished Business”. Moderated by the author, Given the lead time for very senior appointments, our panellists were Denise Wilson OBE, CEO of and being aware first hand that many search the Hampton Alexander Committee, Sir Andrew assignments were immediately put “on hold” when Mackenzie, recently retired CEO of BHP Plc and now the first lockdown was introduced, we expect to see Non-Executive Director at Royal Dutch Shell, and the impact materialise in Q4 and Q1 2021, perhaps Ruth Cairnie, Chair of Babcock International and later. On a positive note, we are seeing a trend of SID at Associated British Foods. We were joined by increasing numbers of women appointed to the 100 FTSE chairs, CEOs and senior directors from the executive director roles.
    [Show full text]
  • Vanguard FTSE International Index Funds Annual
    Annual Report | October 31, 2020 Vanguard FTSE International Index Funds Vanguard FTSE All-World ex-US Index Fund Vanguard FTSE All-World ex-US Small-Cap Index Fund See the inside front cover for important information about access to your fund’s annual and semiannual shareholder reports. Important information about access to shareholder reports Beginning on January 1, 2021, as permitted by regulations adopted by the Securities and Exchange Commission, paper copies of your fund’s annual and semiannual shareholder reports will no longer be sent to you by mail, unless you specifically request them. Instead, you will be notified by mail each time a report is posted on the website and will be provided with a link to access the report. If you have already elected to receive shareholder reports electronically, you will not be affected by this change and do not need to take any action. You may elect to receive shareholder reports and other communications from the fund electronically by contacting your financial intermediary (such as a broker-dealer or bank) or, if you invest directly with the fund, by calling Vanguard at one of the phone numbers on the back cover of this report or by logging on to vanguard.com. You may elect to receive paper copies of all future shareholder reports free of charge. If you invest through a financial intermediary, you can contact the intermediary to request that you continue to receive paper copies. If you invest directly with the fund, you can call Vanguard at one of the phone numbers on the back cover of this report or log on to vanguard.com.
    [Show full text]
  • Right Colon Cancer : Left Behind ?
    Article Right colon cancer : left behind ? GERVAZ, Pascal, BOUCHARDY MAGNIN, Christine, USEL, Massimo Reference GERVAZ, Pascal, BOUCHARDY MAGNIN, Christine, USEL, Massimo. Right colon cancer : left behind ? British Journal of Surgery, 2013, vol. 100, no. s5, p. 8 DOI : 10.1002/bjs.9154 Available at: http://archive-ouverte.unige.ch/unige:90372 Disclaimer: layout of this document may differ from the published version. 1 / 1 SSS abstracts Swiss Society of Surgery The following abstracts will be presented at the 100th Annual Congress of the Swiss Society of Surgery, held in Berne 12–14 June 2013. Visceral of the operation according to a standardised protocol. The patient, the surgeon and the outcome assessors were blinded. Clinical follow-up investigations were Effect of intra-operative infiltration with local anesthesia on the performed after one day, 2 weeks, 1, 3, and 12 months postoperatively. Three development of chronic pain after inguinal hernia repair. A randomized interim analyses with data monitoring committee meetings were performed to controlled triple-blinded trial check whether stopping criteria were met or the sample size had to be adapted. A. Kurmann1,2,H.Fischer3, N. Wippich3, S. Dell-Kuster4,5, The study was stopped after the third interim analysis for futility reasons R. Rosenthal5,J.Metzger3, P. Honigmann3,6 because it was unlikely that significance could be reached within an adequate sample size and time. Chronic postoperative pain was estimated by means of 1 Department of Visceral Surgery, Cantonal Hospital Luzern, Luzern, Switzerland, a Visual Analogue Scale (VAS) and defined as any pain (VAS > 0) 3 months 2 Department of Visceral Surgery and Medicine, University Hospital Bern, Bern, postoperatively.
    [Show full text]
  • 2017 UK Neds A4 Redone CO2.Indd
    The Class of 2016 New NEDs in the FTSE 350 2 FOREWORD At the time I took on my first non-executive role on a FTSE 350 Board, Tony Blair was Prime Minister of the United Kingdom, Steve Jobs had not yet launched the iPhone, and most of us were blissfully unaware of terms such as sub-prime lending, securitisation and credit default swaps. It is hard to believe that the year was 2006, barely over a decade ago. Bob Dylan told us that “times are a-changing” in 1964. But times are certainly changing faster now. From a corporate perspective, it is this speed of evolution – driven by economic, societal, political or technological developments – that keeps management teams and Boards up at night. However, more often than not, what appear as sudden, unexpected changes are but an aggregate of gradual, incremental steps. It is when we do not spot the early “movements” and premonitory signs of change that we find ourselves dangerously exposed to something that, in hindsight, should have been visible to those who had paid attention. As a Chief Executive and a Non-Executive Director I have always looked for those tools that could give me the “upper-hand” in dealing with the unknown and the unexpected. It is for this reason that I welcome The Class of report series published yearly by Korn Ferry. By analysing the small incremental changes occurring from one year to the next in the skills and backgrounds of each new generation of FTSE 350 Directors, and interpreting them in the context of the underlying trends of the past ten years, the Class of provides insight into how our Boards are evolving and, therefore, where companies and – by extension – societies are heading.
    [Show full text]